1. Home
  2. NKTX vs BHST Comparison

NKTX vs BHST Comparison

Compare NKTX & BHST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NKTX
  • BHST
  • Stock Information
  • Founded
  • NKTX 2015
  • BHST 2007
  • Country
  • NKTX United States
  • BHST Canada
  • Employees
  • NKTX N/A
  • BHST N/A
  • Industry
  • NKTX Biotechnology: Pharmaceutical Preparations
  • BHST
  • Sector
  • NKTX Health Care
  • BHST
  • Exchange
  • NKTX Nasdaq
  • BHST Nasdaq
  • Market Cap
  • NKTX 123.5M
  • BHST 106.0M
  • IPO Year
  • NKTX 2020
  • BHST N/A
  • Fundamental
  • Price
  • NKTX $1.74
  • BHST $6.26
  • Analyst Decision
  • NKTX Strong Buy
  • BHST Strong Buy
  • Analyst Count
  • NKTX 6
  • BHST 2
  • Target Price
  • NKTX $14.80
  • BHST $13.00
  • AVG Volume (30 Days)
  • NKTX 422.6K
  • BHST 11.4K
  • Earning Date
  • NKTX 05-14-2025
  • BHST 05-15-2025
  • Dividend Yield
  • NKTX N/A
  • BHST N/A
  • EPS Growth
  • NKTX N/A
  • BHST N/A
  • EPS
  • NKTX N/A
  • BHST N/A
  • Revenue
  • NKTX N/A
  • BHST $27,704,000.00
  • Revenue This Year
  • NKTX N/A
  • BHST $116.40
  • Revenue Next Year
  • NKTX N/A
  • BHST $55.91
  • P/E Ratio
  • NKTX N/A
  • BHST N/A
  • Revenue Growth
  • NKTX N/A
  • BHST 74.76
  • 52 Week Low
  • NKTX $1.31
  • BHST $0.00
  • 52 Week High
  • NKTX $8.23
  • BHST $7.38
  • Technical
  • Relative Strength Index (RSI)
  • NKTX 45.11
  • BHST N/A
  • Support Level
  • NKTX $1.70
  • BHST N/A
  • Resistance Level
  • NKTX $1.82
  • BHST N/A
  • Average True Range (ATR)
  • NKTX 0.10
  • BHST 0.00
  • MACD
  • NKTX -0.01
  • BHST 0.00
  • Stochastic Oscillator
  • NKTX 18.82
  • BHST 0.00

About NKTX Nkarta Inc.

Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.

About BHST BioHarvest Sciences Inc. Common Stock

BioHarvest Sciences Inc is the developer and owner of the patented bio-cell growth platform farming technology. This company is the industrial large-scale plant cell growth technology capable of directly and constantly producing active plant ingredients without the necessity to grow the plant itself. The company is focused on leveraging its botanical synthesis technology to develop the next generation of science-based and clinical therapeutic solutions, within two business verticals - nutraceutical health and wellness products such as dietary supplements, and the development of plant cell-based Active Pharmaceutical Ingredients (APIs) that focus on specific medical indications.

Share on Social Networks: